Merck Kgaa Dm 5 (MKGAF) 85.3000 $MKGAF

Merck KGaA Q2 Earnings Slip Y/Y, 2014 Sales View Confirmed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 15, 8:00AM CDT
Merck KGaA's (MKGAF) second-quarter 2014 earnings per American Depositary Receipt (ADR) came in at $1.52, down 1.8% from the year-ago quarter.

Roche Collaborates with Merck KGaA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 5:30PM CDT
Roche's (RHHBY) Ventana Medical Systems announced that it has entered into an agreement with Germany-based Merck KGaA.

Merck KGaA-Mersana Therapeutics Strike a Deal on ADCs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 4:20PM CDT
Merck KGaA (MKGAF) inked a deal with Mersana Therapeutics for the development of next-generation antibody-drug conjugates (ADCs) for the treatment of cancer.

Merck KGaA-Ono Pharma Deal Ends - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 5:15PM CDT
Merck KGaA (MKGAF) has decided to terminate its license agreement with Ono Pharma related to the development of Ono Pharma's multiple sclerosis candidate, ceralifimod (ONO-4641).

Merck KGaA & MorphoSys Sign Deal, Immuno-Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 3:30PM CDT
Merck KGaA (MKGAF) and MorphoSys inked a deal to discover and develop therapeutic antibodies against undisclosed immune checkpoints.

Merck KGaA/Auxogyn's Eeva System Gets FDA Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 3:40PM CDT
Merck KGaA's (MKGAF) biopharma division, Merck Serono, announced that the FDA has granted clearance to Merck KGaA and partner Auxogyn's Early Embryo Viability Assessment (Eeva) System.

Merck KGaA Enrolls First Patient in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:28PM CDT
Merck KGaA enrolled the first patient in a phase III study (ESPART) on Pergoveris

Merck KGaA Misses 2013 Earnings & Rev Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 9:30AM CST
Merck KGaA reported 2013 earnings per ADR of $11.70, up 19.2% year over year but below the Zacks Consensus Estimate of $11.99.

Avanir Reports Narrower Loss, Revs Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 11:40AM CST
Avanir Pharma reported first quarter fiscal 2014 net loss per share of 7 cents, narrower than the Zacks Consensus Estimate of a loss of 8 cents

Threshold Pharma Completes Enrolment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 3:45PM CST
Threshold Pharma completed enrolling patients in its phase III study, which is being conducted to evaluate TH-302 for the treatment of advanced soft tissue sarcoma.

Avanir Reports Wider Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 11, 8:37AM CST
Avanir reported 4Q13 net loss per share of 10 cents, wider than the Zacks Consensus Estimate of a loss of 7 cents

Threshold Pharma's TH-302 in Melanoma Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 15, 12:00PM CDT
Threshold Pharmaceuticals recently initiated a phase II trial on its pipeline candidate, TH-302.

Update on Threshold Pharma's TH-302 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 08, 10:20PM CDT
Threshold Pharma announced an amendment in the protocol for its pivotal phase III study of TH-302

Sanofi's Lemtrada Gets CHMP Backing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 01, 11:40AM CDT
The Committee for Medicinal Products for Human Use recommended the approval of Lemtrada

Data on Merck KGaA's L-BLP25 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 22, 9:00PM CDT
Merck KGaA presented detailed results on its oncology candidate L-BLP25, from the phase III study, START.

Merck KGaA Posts Higher Y/Y Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 15, 10:24AM CDT
Merck KGaA reported first quarter 2013 earnings per American Depository Receipt (ADR) of $2.79, up 28.1% year over year.

Merck KGaA-CBRX Renew Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 11, 3:00PM CDT
Merck KGaA and Columbia Labs renewed a license and supply agreement for Crinone (progesterone gel), extending it for an additional five years

Sanofi Reports Lemtrada Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 27, 4:30PM CDT
Sanofi's subsidiary, Genzyme, announced interim data on Lemtrada.

Merck KGaA-BMY Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 21, 4:15PM CDT
Merck KGaA announced a deal with Bristol-Myers Squibb for the promotion of different formulations of Glucophage (metformin hydrochloride) in China.

Merck KGaA - Nordic Bioscience Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 20, 4:00PM CDT
Merck KGaA recently announced a strategic deal with Nordic Bioscience Clinical Development A/S for its pipeline candidate, sprifermin.